Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Ira von Carlowitz"'
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
The cytokine interleukin 1α (IL-1α) plays an important role in inflammatory processes. Here the authors use SELEX to generate a modified DNA aptamer which specifically binds IL-1α, present the structure of the IL-1α/aptamer complex and show that
Externí odkaz:
https://doaj.org/article/e2cdd527a9be48b8adaaa6d5896332bd
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
Nature Communications
Nature Communications
IL-1α is an essential cytokine that contributes to inflammatory responses and is implicated in various forms of pathogenesis and cancer. Here we report a naphthyl modified DNA aptamer that specifically binds IL-1α and inhibits its signaling pathway
Autor:
John C. Rohloff, Daniel Schneider, Nebojsa Janjic, Jeffrey D. Carter, Bharat Gawande, Ira von Carlowitz, Chi Zhang
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 114(11)
The nucleobases comprising DNA and RNA aptamers provide considerably less chemical diversity than protein-based ligands, limiting their versatility. The introduction of novel functional groups at just one of the four bases in modified aptamers has re
Autor:
Eli M. Wallace, Francis X. Sullivan, Yvan Le Huerou, Stefan D. Gross, Jennifer Garrus, P LouAnn Cable, Richard Woessner, Kurtis D. Davies, Ira von Carlowitz
Publikováno v:
Cancer Biology & Therapy. 12:788-796
Inhibition of the checkpoint kinase Chk1, both as a monotherapy and in combination with DNA damaging cytotoxics, is a promising therapeutic approach for the treatment of a wide array of human cancers. However, much remains to be elucidated in regard
Autor:
Ira von Carlowitz, Anke Klippel, Anett Schmiedeknecht, Frank Gebhardt, Klaus Giese, Anny Kretschmer, Frauke Leenders, Maria Sternberger, Leonid Beigelman, Frank Czauderna, Mike Engle
Publikováno v:
Antisense and Nucleic Acid Drug Development. 12:131-143
The study of signal transduction processes using antisense oligonucleotides is often complicated by low intracellular stability of the antisense reagents or by nonspecific effects that cause toxicity. Here, we introduce a new class of antisense molec
Autor:
Anna M. Randi, Fiona McLaughlin, Suzy Brown, Ira von Carlowitz, Joanne M. Cox, Valerie J. Ludbrook
Publikováno v:
Blood. 98:3332-3339
It has recently been shown that the transcription factor Erg, an Ets family member, drives constitutive expression of the intercellular adhesion molecule 2 (ICAM-2) in human umbilical vein endothelial cells (HUVECs) and that its expression is down-re
Publikováno v:
Molecular and General Genetics MGG. 229:453-459
The nucleotide sequence of the Escherichia coli K12 beta-methylgalactoside transport operon, mgl, was determined. Primer extension analysis indicated that the synthesis of mRNA initiates at guanine residue 145 of the determined sequence. The operon c
Autor:
Kristal Domenico, Ira von Carlowitz, Dennis Macejak, Nilabh Chaudhary, Andrew Conrad, Pamela Pavco, Kristi Jensen, Laurent Bellon, Sharon Jamison, Lawrence M. Blatt, Myron J. Tong, Elisabeth Roberts
Publikováno v:
Hepatology (Baltimore, Md.). 31(3)
Ribozymes are catalytic RNA molecules that can be designed to cleave specific RNA sequences. To investigate the potential use of synthetic stabilized ribozymes for the treatment of chronic hepatitis C virus (HCV) infection, we designed and synthesize
Autor:
Karyn Bouhana, Steven D. Andrews, Shannon L. Winski, Taylor J. Alford, Ira von Carlowitz, Patrice Lee, Richard Woessner, Anna Gomez
Publikováno v:
Cancer Research. 72:1798-1798
The Trk family of genes, which includes trkA/NTRK1, trkB/NTRK2 and trkC/NTRK3, encode the tyrosine kinase receptors for the neurotrophin family of nerve growth factors. Deregulated kinase activity of trk family members is associated with human cancer
Autor:
Yvan Le Huerou, Francis J. Sullivan, Eli M. Wallace, Ira von Carlowitz, Richard Woessner, Stefan Gross, Kurtis D. Davies
Publikováno v:
Cancer Research. 71:2939-2939
Inhibition of the checkpoint kinase Chk1, both as a monotherapy and in combination with DNA damaging cytotoxics, is a promising therapeutic strategy for human cancer. However, much remains to be learned in regard to the patient populations that will